Optimal cut-off values for anthropometric measures of obesity in screening for cardiometabolic disorders in adults

Macek, Paweł; Biskup, Małgorzata; Terek-Derszniak, Małgorzata; Król, Halina; Smok-Kalwat, Jolanta; Góźdż, Stanisław; Žák, Marek

doi:10.1038/s41598-020-68265-y

Cited by 31 publications

(27 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending on individual predispositions, over the course of one’s life span, body weight is subject to gradual growth characterised by different dynamics, depending on individual lifestyle, as well as numerous environmental and genetic factors [ 1 ]. Body weight gain leading to obesity is a generally acknowledged health hazard, and a major risk factor for cardiovascular diseases (CVDs) [ 2 , 3 , 4 , 5 ]. Specific guidelines issued by the American Heart Association/American College of Cardiology/The Obesity Society (AHA/ACC/TOS) unequivocally support the consensus on the health benefits stemming from weight loss [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults

Macek

Terek-Derszniak

Biskup

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Modest weight loss enhances clinical control over cardiovascular disease (CVD) risk factors in overweight and obese individuals. This study aimed to assess the associations between individual weight loss and predefined criteria for clinical improvement in blood pressure, lipid levels, and glycemia. A two-year follow-up study involved 3388 (37.9% men) aged 45−64 years, BMI ≥ 25 kg/m2. Changes in body weight were calculated as a percentage of baseline weight; outcome variables: systolic (SBP), diastolic (DBP) blood pressure, high-density (HDL-C) and low-density (LDL-C) lipoproteins, fasting blood glucose (FBG), and triglycerides (TG) were construed as the differences between baseline and outcome values. Clinically significant improvement was defined as SBP/DBP reduction by 5 mm/Hg, FBG−20 mg/dL, LDL-C-10 mg/dL, TG−40 mg/dL, and HDL-C increase by 5 mg/dL. Apart from LDL-C, a modest 5%–10% weight loss was associated with clinically significantly improved outcomes. The incident rate ratios and 95% confidence intervals for clinical improvement of SBP were: 1.27 (1.14–1.40), DBP/1.30 (1.12–1.50), HDL/1.54 (1.18–2.02), and TG/1.69 (1.32–2.17). In the higher category of weight loss, associations were still manifest, although the results proved diagnostically challenging (low number of cases). Even though modest weight loss does enhance clinical control over CVD risk factors, offering regular medical guidance to patients is postulated to further boos the anticipated outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults

Macek

Terek-Derszniak

Biskup

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…In particular, the adoption of a Western Diet, characterized by a high consumption of ultra-processed foods, rich in saturated fat with high caloric density, may be a determining aspect for overweight in the population of this study 37,38 .…”

Section: Discussionmentioning

confidence: 95%

Protein intake and its influence on the lipid and anthropometric profiles of patients with chronic kidney disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…An important limitation of this study could be the unavailability of individual-level data, which could have enabled us to confirm the absence of pleiotropic variants by using various potential confounding variables between WHR and PD. For instance, it is known that different markers of obesity show gender specific cut-offs and possibility of specific gender in influencing the observed causal estimates cannot be ruled out 54, 55 . Although we observed a suggestive reverse causal association of T2D with PD using different MR methods, we did not observe similar results with HbA1C, which is a known biomarker for prediabetes or diabetes.…”

Section: Discussionmentioning

confidence: 99%

A Mendelian randomization study of glycemic and anthropometric traits and Parkinson’s disease

Grover

Graf

Noyce

et al. 2020

Preprint

View full text Add to dashboard Cite

ImportanceImpaired glucose and obesity are known characteristics of patients with PD, although it is unclear whether the dysfunction precedes or results from the neurodegeneration.ObjectiveTo assess whether glycemic traits and anthropometric traits can influence the risk of PD in 33,674 cases and 449,056 healthy controls using Mendelian randomization (MR) framework.Design, setting, and participantsWe investigated causality with a two-sample bidirectional MR approach in the European population. We used the inverse variance-weighted (IVW), weighted median (WME), and weighted mode (MBE) methods to compute effect estimates with summary statistics from available meta-analyses of genome-wide association studies (GWAS) on glycemic and anthropometric traits that used discovery cohorts. We conducted sensitivity analyses with prioritized genetic instruments that used different study designs including employment of different study cohorts and body mass index (BMI) adjusted exposures, and exclusion of overlapping samples between risk factors and outcome datasets, and potential pleiotropic genetic instruments.Main outcome and measuresPD, glycemic and anthropometric traitsResultsWe observed a risky effect of PD on fasting glucose (FG) (IVW: β = 0.0188 per log-odds of PD; 95% CI 0.0062–0.0313, p-value = 0.0055). We further observed a protective effect of PD on type 2 diabetes (T2D) (WME: OR = 0.946 per log-odds of PD; 95% CI 0.929–0.983, p-value = 0.0051). A direct causal role of waist-hip ratio (WHR) was also observed in PD (IVW OR = 0.735; 95% CI = 0.622-0.868 per 1-SD of WHR, p = 0.0003). However, the association was lost after WHR was adjusted for body mass index (BMI) (IVW OR = 0.889; 95% CI = 0.779-1.037 per 1-SD of WHR adjusted for BMI, p = 0.1429) indicating that the observed association is mediated via BMI The associations were further retained after the exclusion of overlapping UK Biobank (UKB) samples in the PD dataset.Conclusions and relevanceOur results showed that PD patients are glucose tolerant with protection against T2D. Furthermore, central obesity may be protective against PD development, independent of glucose levels. The implication of different indices of glycemic control and body fat distribution on the PD symptomatology deserves further investigation.Key pointsQuestionAre glucose and obesity associated with Parkinson’s disease?FindingsUsing bi-directional Mendelian randomization (MR) approach, and using Parkinson disease (PD) as an exposure, our study found that a 1-log odds increase in genetic predisposition to PD was associated with 0.0188 mmol/l increase in fasting glucose concentration. The genetic predisposition to PD was also associated with a 5.4% lower risk of type-2 diabetes (T2D). We found that a 1-SD increase in waist-hip ratio (WHR) was associated with a 26.5% lower risk of PD in the European population, likely to be mediated via body mass index.MeaningA strong genetic predisposition towards glucose tolerance was observed in PD patients. and PD patients are protective against T2D. Further, an increase in WHR lowers the risk of PD. Our study thereby suggests potential roles of body fat distribution and glycemic traits on PD symptomatology.

show abstract

Optimal cut-off values for anthropometric measures of obesity in screening for cardiometabolic disorders in adults

Cited by 31 publications

References 56 publications

A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults

A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults

Protein intake and its influence on the lipid and anthropometric profiles of patients with chronic kidney disease

A Mendelian randomization study of glycemic and anthropometric traits and Parkinson’s disease

Contact Info

Product

Resources

About